About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGPhase 1

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Intracellularly Prepared Chimeric Antigen Receptor T-cell Therapy Targeting CD19 for the Treatment of Relapsed/Refractory Hematological Malignancies

NCT07239323•Chongqing Precision Biotech Co., Ltd

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

B-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma

Interventions

Invivo CAR-T

Locations

1

China

Locations (1)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Kunming, Yunnan, China

Key Dates

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2028

Last Updated

November 20, 2025

Related Studies

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528

Non-hodgkin LymphomaMultiple Myeloma

RECRUITINGPhase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101

Multiple MyelomaNewly Diagnosed Multiple Myeloma

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860

Advanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+42 more

RECRUITINGPhase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402

Multiple Myeloma

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT06383143

AL AmyloidosisSmoldering Multiple Myeloma+1 more

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760

Clonal Hematopoiesis of Indeterminate PotentialMonoclonal Gammopathy+4 more

View all related studies

Contacts

Wang Sanbin, PhD

CONTACT

+86 13187424131 sanbin1011@163.com

Sponsors

Lead Sponsor

Chongqing Precision Biotech Co., Ltd

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 20, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions